Israel Active

Israel’s Sheba Medical Center has just delivered three sets of triplets on the same day - a unique occasion. The three mothers had carried for 30 -32 weeks. Co-incidentally, World Premature Day is recognized on 17th Nov around the world. Last year, 77 women in Israel gave birth to triplets.

The results of a quantitative study at two Israeli medical clinics have proved that medical clowns relieve the anxiety of children towards invasive medical examinations. Lowering anxiety levels shortens procedure time and reduces pain (e.g. of a colonoscopy).

We’ve just returned from Jerusalem. The hotel where we stayed was also hosting the UNESCO 13th World Conference on Bioethics, Medical Ethics and Health Law and many of the international delegates were pleased to hear about VeryGoodNewsIsrael.  

I reported previously on Israel’s RightHear and its app that enables the visually impaired to navigate shopping malls, hospitals, universities etc. RightHear has since been installed in Israeli supermarket chain Shufersal, launched in the US and is heading for the UK.

The US Biomedical Advanced Research and Development Authority (BARDA) has invested $43 million in Israel’s MediWound to develop its NexoBrid product for the treatment of mustard gas injuries. In 2015 BARDA invested $112 million to help MediWound develop NexoBrid for burns.

I reported previously that the PMD200 pain measurement device from Israel’s Medasense had received European CE Approval. Now, the international Society of Critical Care Medicine has included the innovative technology in its Intensive Care Unit Clinical Practice Guidelines.

Hospitals all over the world use Israeli medical technology. But Israeli Artificial Intelligence (AI) is the next big item. This article highlights Israel’s MedAware (preventing prescription errors), MobiGuide’s Patient Guidance system, Zebra Medical, and AI systems at Israeli hospitals Sheba and Sourasky.

I reported previously on Israel’s Medi-Tate and its non-invasive treatment for benign prostate enlargement.  Now Japan’s Olympus Corporation has invested $20 million in Medi-Tate and will market Medi-Tate’s iTind implant in several countries.

I reported previously on Israel’s PixCell which received a multi-million grant by the EU to help advance its HemoScreen portable blood test.  The US FDA has just approved HemoScreen to sell in the USA. Meanwhile, Israel’s SightDx has launched its OLO blood tester.

I reported previously on Israel’s MedyMatch and its Artificial Intelligent Accipio Ix intracranial hemorrhage detection software.  MedyMatch (renamed MaxQ AI) has now received both FDA and CE approval to sell its systems in both the US and in Europe.